Semaglutide formulations compared for pharmacokinetics and pen-injector performance in overweight/obesity
Background
Both obesity and overweight represent significant global health challenges, necessitating continuous innovation in therapeutic strategies. Semaglutide, a potent GLP-1 receptor agonist, has demonstrated substantial efficacy in weight management and cardiovascular risk reduction. However, the landscape of drug delivery systems and specific formulations is constantly evolving to enhance patient convenience, adherence, and broader accessibility. This study specifically addresses the need to thoroughly evaluate the pharmacokinetic profiles and performance characteristics of novel subcutaneous semaglutide formulations delivered via distinct pen-injectors. These particular forms currently lack regulatory approval for obesity treatment, highlighting the importance of this foundational pharmacokinetic assessment.